<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="466">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04377750</url>
  </required_header>
  <id_info>
    <org_study_id>0224-20-HMO-CTIL</org_study_id>
    <nct_id>NCT04377750</nct_id>
  </id_info>
  <brief_title>The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation</brief_title>
  <official_title>The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wolfson Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Title: The use of Tocilizumab in the management of patients who have severe COVID-19 with
      suspected pulmonary hyperinflammation.

      This is a study designed to assess the therapeutic value of intravenous tocilizumab
      administered as single 8mg/Kg dose in patients affected by SARS-CoV2 infection with a
      pulmonary manifestation causing hypoxia. Aim of the study is to test the hypothesis that
      anti-IL6 treatment can be effective in reducing the virus-induced cytokine storm, blocking
      deterioration of lung function or even promoting a rapid improvement of clinical conditions,
      preventing tracheal intubation and/or death.

      This drug will be administered to those patients entering the ICU with severe acute
      respiratory failure COVID-19 disease. The endpoints are death and duration of
      hospitalization. The patients will be assessed with surrogate markers determining the level
      of the cytokine storm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design This is a multicenter, two arms, 2:1 (treatment: control) open-label randomized
      control study with a drug approved for another indication in Israel. All the patients
      enrolled will be treated with tocilizumab or not. One-month mortality rate is the primary
      endpoint. One arm will be the study drug anti-IL6R (Tocilizumab (Actmera)) 8 mg/kg given IV
      during one hour once. The placebo will be a 100 ml saline IV infusion administered along one
      hour.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2020</start_date>
  <completion_date type="Anticipated">May 8, 2021</completion_date>
  <primary_completion_date type="Actual">April 29, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>One-month</time_frame>
    <description>One-month mortality rate .</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Covid19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>Tocilizumab treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment: intravenous administration of monoclonal anti body anti- IL6R. The dose is 8 mg/kg up to total dose of 800 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo. intravenous administration of 100 ml of normal saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>The placebo treatment arm will include 100 ml of normal saline administered along 60 min</description>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_label>Tocilizumab treatment group</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Any gender

          2. Age 18 and older

          3. Informed consent for participation in the study

          4. Virological diagnosis of Sars-CoV2 infection (PCR)

          5. Acute respiratory failure

          6. Radiographic pneumonia, defined as any/ changing new lung infiltrate

          7. Patient breathing spontaneously, required more than 50% oxygen and MEWS score &gt; 7.

          8. If intubated, intubated less than 24 hours with PaO2/Fio2 ratio ≤ 200 and PEEP ≥ 5 cm
             H2O.

        Exclusion Criteria:

          1. Known hypersensitivity to tocilizumab or its excipients

          2. Patient with a life expectancy of less than 6 months.

          3. Known active infections or other clinical condition that contra-indicate tocilizumab
             and cannot be treated or solved according to the judgement of the clinician.

          4. Neutrophils &lt;500 / mmc

          5. Platelets &lt;40.000 / mmc
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juli Benbenisty, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Hadassah Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reuven Pizov, Prof.</last_name>
    <phone>972-50-6265542</phone>
    <email>pizovr@hadassah.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eithan Galun, Prof.</last_name>
    <phone>972-2-6777762</phone>
    <email>eithang@hadassah.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hadassah Medical Orginisation</name>
      <address>
        <city>Jerusalem</city>
        <state>Please Select:</state>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eithan Galun, Prof.</last_name>
      <phone>972-2-6777762</phone>
      <email>eithang@hadassah.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shlomo Maayan, PROF</last_name>
      <phone>972-5-37678965</phone>
      <email>shlomomom@bmc.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>H̱olon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasmin Meir, Dr.</last_name>
      <phone>972-5-26666194</phone>
      <email>yasminm@wmc.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galia Rahav, Prof.</last_name>
      <phone>972-5-526666190</phone>
      <email>galia.rahav@sheba.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>May 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Cytokine storm</keyword>
  <keyword>IL-6</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

